Dr. Charles O'Neill
BioMarin Pharmaceutical Inc, Vice President
Charles A. O’Neill, Ph.D., joined BioMarin in 2003 and currently serves as Vice President and Head of Early Drug Development Solutions. Prior to this role, from 2007 to 2020, Dr. O’Neill served as Vice President, Pharmacological Sciences, overseeing the nonclinical development of BioMarin’s late-stage research and clinical drug candidates along with providing nonclinical support to BioMarin commercial products. He has also contributed to the nonclinical development of therapies for achondroplasia, hemophilia A, PKU and hereditary angioedema.
From 1996 to 2003, Dr. O’Neill was in Safety Assessment at Genentech, Inc., where he led nonclinical development for the anti-angiogenic monoclonal antibody Avastin and Lucentis. Before Genentech, Dr. O’Neill was an Assistant Research Professor at the UC Davis School of Medicine. Dr. O’Neill has coauthored more than 80 peer-reviewed publications. He received a Ph.D. in veterinary pharmacology and toxicology from the UC, Davis and was a postdoctoral fellow at the National Heart Lung and Blood Institute.
Sessions
CRS Award Winners
From 1996 to 2003, Dr. O’Neill was in Safety Assessment at Genentech, Inc., where he led nonclinical development for the anti-angiogenic monoclonal antibody Avastin and Lucentis. Before Genentech, Dr. O’Neill was an Assistant Research Professor at the UC Davis School of Medicine. Dr. O’Neill has coauthored more than 80 peer-reviewed publications. He received a Ph.D. in veterinary pharmacology and toxicology from the UC, Davis and was a postdoctoral fellow at the National Heart Lung and Blood Institute.
Sessions
CRS Award Winners
